| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Actym Therapeutics |
| Recipient: You |
| Company: Pyxis |
| Recipient: You |
| Company: Tempest Therapeutics |
| Recipient: You |
| Company: Kanaph Therapeutics |
| Recipient: You |
| Company: Onc.AI |
| Recipient: You |
| Company: NeoTX |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Tempest Therapeutics |
| Recipient: You |
| Company: Alphamab Oncology |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Incyte |
| Recipient: You |
| Company: Werewolf |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Xilio |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Bright Peak |
| Recipient: You |
| Company: Onc.AI |
| Recipient: You |
| Company: Hotspot Therapeutics |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Merck |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Macrogenics |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Immatics |
| Recipient: Your Institution |
| Company: Moderna Therapeutics |
| Recipient: Your Institution |
| Company: Ikena Oncology |
| Recipient: Your Institution |
| Company: Numab |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Tizona Therapeutics, Inc. |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Serial #15/612,657 (Cancer Immunotherapy), |
| Recipient: You |
| Please describe: Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
|
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Merck |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|